MDGL

434.80

2.10% 8.95

시장 영업 전: 440.64 5.84 +1.34%

Madrigal Pharmaceuticals Inc (MDGL)

개요 뉴스 가격 이력 옵션 체인 Financials MDGL 왜 하락? 토론 예측 주식 분할

전일 마감가:

$425.85

열려 있는:

$429.86

하루 거래량:

265.11K

Relative Volume:

0.79

시가총액:

$9.87B

수익:

순이익/손실:

$-518.67M

주가수익비율:

-17.31

EPS:

-25.12

순현금흐름:

$-438.32M

1주 성능:

-0.05%

1개월 성능:

-9.15%

6개월 성능:

+0.83%

1년 성능:

+35.32%

1일 변동 폭

$423.98

$443.61

1주일 범위

$416.21

$448.13

52주 변동 폭

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

명칭

Madrigal Pharmaceuticals Inc

부문

Healthcare (1106)

산업

Biotechnology (621)

전화

404-380-9263

주소

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

직원

528

트위터

@MadrigalPharma

다음 수익 날짜

2024-10-31

최신 SEC 제출 서류

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
MDGL Madrigal Pharmaceuticals Inc	434.80	9.67B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-01-28	개시	Barclays	Overweight
2026-01-06	다운그레이드	Wolfe Research	Outperform → Peer Perform
2025-11-05	업그레이드	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	업그레이드	BofA Securities	Underperform → Neutral
2025-10-15	개시	Truist	Buy
2025-09-04	재개	H.C. Wainwright	Buy
2025-02-28	업그레이드	B. Riley Securities	Neutral → Buy
2025-02-27	재확인	H.C. Wainwright	Buy
2024-06-28	개시	Cantor Fitzgerald	Neutral
2024-06-11	개시	Wolfe Research	Outperform
2024-04-22	개시	BofA Securities	Underperform
2024-03-15	업그레이드	B. Riley Securities	Sell → Neutral
2024-03-06	개시	Citigroup	Buy
2024-02-26	다운그레이드	B. Riley Securities	Neutral → Sell
2022-12-20	재확인	Oppenheimer	Outperform
2022-12-19	재확인	H.C. Wainwright	Buy
2022-12-19	재확인	Piper Sandler	Overweight
2022-12-19	업그레이드	Raymond James	Underperform → Mkt Perform
2022-07-08	다운그레이드	B. Riley Securities	Buy → Neutral
2021-10-07	개시	Jefferies	Buy
2021-08-06	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-05-20	재개	Goldman	Buy
2020-11-24	재개	Evercore ISI	Outperform
2020-11-06	재확인	H.C. Wainwright	Buy
2020-07-31	개시	Piper Sandler	Overweight
2020-06-05	개시	BMO Capital Markets	Market Perform
2020-05-05	개시	Chardan Capital Markets	Buy
2020-01-30	개시	Canaccord Genuity	Buy
2020-01-09	업그레이드	UBS	Neutral → Buy
2019-11-07	재확인	H.C. Wainwright	Buy
2019-06-25	개시	Stifel	Hold
2019-06-10	업그레이드	B. Riley FBR	Neutral → Buy
2019-02-28	재확인	H.C. Wainwright	Buy
2019-02-22	개시	SVB Leerink	Outperform
2019-01-23	개시	UBS	Neutral
2018-12-14	개시	Wolfe Research	Outperform
2018-12-12	개시	B. Riley FBR	Neutral
2018-11-19	다운그레이드	Raymond James	Mkt Perform → Underperform
2018-11-16	업그레이드	Evercore ISI	In-line → Outperform
2018-09-04	개시	Citigroup	Buy
2018-08-06	다운그레이드	Goldman	Buy → Neutral
2018-06-28	개시	Raymond James	Mkt Perform

모두보기

Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스

06:27 AM

Segall Bryant & Hamill LLC Invests $10.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

06:27 AM

01:39 AM

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - simplywall.st

01:39 AM

Mar 04, 2026

Madrigal Pharmaceuticals: How Noninvasive Data Is Powering a Smarter Clinical Strategy! - Smartkarma

Mar 04, 2026